Crotaline (Monocrotaline)
(Synonyms: 野百合碱; Crotaline) 目录号 : GN10512
Crotaline 是一种从 Crotalaria spectabilis 植物种子中提取的吡咯里西啶生物碱，可诱导大鼠肺血管综合征。
Cas No.:315-22-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Crotaline is an pyrrolizidine alkaloid extracted from the seeds of the Crotalaria spectabilis plant to induce pulmonary vascular syndrome in rats[1]. crotaline a natural ligand exhibits dose-dependent cytotoxicity with potent antineoplastic activity. The in vitro cytotoxicity of crotaline is proved at IC50 24.966 μg/mL and genotoxicity at 2 X IC50 against HepG2 cells[2].
In the absence of HepaRG hepatocytes, even at significantly high concentration (1200 μM) for 24 h treatment, Crotaline did not affect viability of HSECs, indicating no cytotoxicity. In contrast, after 24 h treatment in the two-layer transwell co-culture model with co-culture of HSECs and HepaRG hepatocytes, significant decrease in HSEC viability in a concentration-dependent manner was observed for Crotaline[8].
Crotaline causes pulmonary vascular syndrome in rats, characterized by proliferative pulmonary vasculitis, pulmonary hypertension (PH), and cor pulmonale[3].Changes in multiple pathways associated with PH development were observed by crotaline injection, including activated glycolysis, increased proliferation markers, disruption of carnitine homeostasis, increased inflammatory and fibrotic biomarkers, and decreased glutathione biosynthesis[5].Using rats (14 days after exposure to crotaline), changes in multiple pathways associated with the development of PH, including activated glycolysis, increased markers of proliferation, disruptions in carnitine homeostasis, increased inflammatory and fibrosis biomarkers, and a reduction in glutathione biosynthesis[4].PAH induced by Crotaline is a progressive disease with persistent inflammation. The inflammation in Crotaline -PAH model includes acute (the first 6 days after Crotaline injection) and chronic stages (after acute inflammation stage). Acute inflammation stage may be the time window of anti-inflammatory treatment in PAH induced by Crotaline [6,7].
References:
[1]: Gomez-Arroyo JG, Farkas L, et,al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 2012 Feb 15;302(4):L363-9. doi: 10.1152/ajplung.00212.2011. Epub 2011 Sep 30. PMID: 21964406.
[2]: Kusuma SS, Tanneeru K, et,al. Antineoplastic activity of monocrotaline against hepatocellular carcinoma. Anticancer Agents Med Chem. 2014;14(9):1237-48. doi: 10.2174/1871520614666140715085907. PMID: 25028149.
[3]: Wilson DW, Segall HJ, et,al. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol. 1992;22(5-6):307-25. doi: 10.3109/10408449209146311. PMID: 1489509.
[4]: Nogueira-Ferreira R, Vitorino R, et,al. Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach. Pulm Pharmacol Ther. 2015 Dec;35:8-16. doi: 10.1016/j.pupt.2015.09.007. Epub 2015 Sep 21. PMID: 26403584.
[5]: Rafikova O, Meadows ML, et,al. Metabolic Changes Precede the Development of Pulmonary Hypertension in the Monocrotaline Exposed Rat Lung. PLoS One. 2016 Mar 3;11(3):e0150480. doi: 10.1371/journal.pone.0150480. PMID: 26937637; PMCID: PMC4777490.
[6]: Tang C, Luo Y, et,al. Characteristics of inflammation process in monocrotaline-induced pulmonary arterial hypertension in rats. Biomed Pharmacother. 2021 Jan;133:111081. doi: 10.1016/j.biopha.2020.111081. Epub 2020 Dec 15. PMID: 33378977.
[7]: Nogueira-Ferreira R, Vitorino R, et,al. Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach. Pulm Pharmacol Ther. 2015 Dec;35:8-16. doi: 10.1016/j.pupt.2015.09.007. Epub 2015 Sep 21. PMID: 26403584.
[8]: Lu Y, Ma J, Lin G. Development of a two-layer transwell co-culture model for the in vitro investigation of pyrrolizidine alkaloid-induced hepatic sinusoidal damage. Food Chem Toxicol. 2019 Jul;129:391-398. doi: 10.1016/j.fct.2019.04.057. Epub 2019 May 2. PMID: 31054999.
Crotaline 是一种从 Crotalaria spectabilis 植物种子中提取的吡咯里西啶生物碱，可诱导大鼠肺血管综合征[1]。 crotaline 是一种天然配体，具有剂量依赖性细胞毒性和强大的抗肿瘤活性。 crotaline 的体外细胞毒性为 IC50 24.966 μg/mL，对 HepG2 细胞的遗传毒性为 2 X IC50[2]。
在没有 HepaRG 肝细胞的情况下，即使在显着高浓度 (1200 μM) 下处理 24 小时，Crotaline 也不影响 HSEC 的活力，表明没有细胞毒性。相比之下，在 HSECs 和 HepaRG 肝细胞共培养的双层 transwell 共培养模型中处理 24 h 后，观察到 Crotaline 浓度依赖性显着降低 HSEC 活力[8].
Crotaline 引起大鼠肺血管综合征，以增殖性肺血管炎、肺动脉高压 (PH) 和肺心病为特征[3]。通过 crotaline 注射液观察与 PH 发展相关的多条通路的变化，包括激活的糖酵解、增殖标志物增加、肉碱稳态破坏、炎症和纤维化生物标志物增加以及谷胱甘肽生物合成减少[5]。使用大鼠（暴露于 crotaline 后 14 天），多条通路发生变化PH 的发展相关，包括激活的糖酵解、增殖标志物增加、肉碱稳态破坏、炎症和纤维化生物标志物增加以及谷胱甘肽生物合成减少[4]。Crotaline 诱导的 PAH 是一种具有持续炎症的进行性疾病。 Crotaline-PAH模型中的炎症包括急性（Crotaline注射后的前6天）和慢性阶段（急性炎症阶段后）。急性炎症期可能是百合碱诱导PAH抗炎治疗的时间窗[6,7]。
| Cell experiment [1]: | |
|
Cell lines |
HepaRG hepatocytes and HSECs |
|
Preparation Method |
HSECs were treated with different concentrations of retrorsine, crotaline (monocrotaline) or clivorine dissolved in ECM containing DMSO (0.5% final concentration) or ECM containing 0.5% DMSO as solvent controls in two-layer transwell co-culture model for 24 h. |
|
Reaction Conditions |
100-1200uM,24h |
|
Applications |
In the absence of HepaRG hepatocytes, even at significantly high concentration (1200 μM) for 24 h treatment, Crotaline did not affect viability of HSECs, indicating no cytotoxicity. In contrast, after 24 h treatment in the two-layer transwell co-culture model with co-culture of HSECs and HepaRG hepatocytes, significant decrease in HSEC viability in a concentration-dependent manner was observed for Crotaline. |
| Animal experiment [2]: | |
|
Animal models |
20 male Sprague Dawley rats (SD; 220-270g) |
|
Preparation Method |
Control group received vehicle for crotaline. Pre-pulmonary hypertension (PH) group received a single injection of Crotaline to induce and were sacrificed after 14 days. |
|
Dosage form |
A single injection crotaline 60 mg/kg for 14 days |
|
Applications |
Changes in multiple pathways associated with PH development were observed by crotaline injection, including activated glycolysis, increased proliferation markers, disruption of carnitine homeostasis, increased inflammatory and fibrotic biomarkers, and decreased glutathione biosynthesis. |
|
References: [1]. Lu Y, Ma J, Lin G. Development of a two-layer transwell co-culture model for the in vitro investigation of pyrrolizidine alkaloid-induced hepatic sinusoidal damage. Food Chem Toxicol. 2019 Jul;129:391-398. doi: 10.1016/j.fct.2019.04.057. Epub 2019 May 2. PMID: 31054999. [2]. Nogueira-Ferreira R, Vitorino R, et,al. Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach. Pulm Pharmacol Ther. 2015 Dec;35:8-16. doi: 10.1016/j.pupt.2015.09.007. Epub 2015 Sep 21. PMID: 26403584. |
|
| Cas No. | 315-22-0 | SDF | |
| 别名 | 野百合碱; Crotaline | ||
| 化学名 | (3R,4R,5R,8a1R,13aR)-4,5-dihydroxy-3,4,5-trimethyl-4,5,8,8a1,10,12,13,13a-octahydro-2H-[1,6]dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3H)-dione | ||
| Canonical SMILES | O=C([C@@](C([H])([H])[H])([H])[C@@]([C@@]1(C([H])([H])[H])O[H])(C([H])([H])[H])O[H])O[C@@]2([H])[C@](C(C([H])([H])OC1=O)=C([H])C3([H])[H])([H])N3C([H])([H])C2([H])[H] | ||
| 分子式 | C16H23NO6 | 分子量 | 325.15 |
| 溶解度 | ≥ 67.2 mg/mL in DMSO, ≥ 16.45 mg/mL in ETOH with ultrasonic and warming, ≥ 1.66 mg/mL in Water with ultrasonic and warming | 储存条件 | 4°C, away from moisture and light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0755 mL | 15.3775 mL | 30.755 mL |
| 5 mM | 0.6151 mL | 3.0755 mL | 6.151 mL |
| 10 mM | 0.3076 mL | 1.5378 mL | 3.0755 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet